Powered by
GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017

GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that pre-clinical research demonstrating the potential of two of its drug candidates, GMI-1271 and GMI-1359, against multiple myeloma will be shared via an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, DC. The company and its collaborators at Washington University in St. Louis will highlight data on GMI-1271 , an antagonist of E-selectin, and GMI-1359 , a dual antagonist of E-selectin

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox